Professor of Medicine, University Wisc
Oncology
Dr. George Wilding, MD
|
|
Give Review
George Wilding practices Oncology. He went to medical school at University of Massachusetts Medical School. University of Massachusetts Medical School has a rank of 49 in research and a 12 in primary care He received 2 awards: "America's Top Doctors" and "America's Top Doctors for Cancer". Dr. George Wilding is also a published doctor. He has 19 paper published. The most recent paper is: Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Publications
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic Renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
- A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate Cancer.
- A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: E...
- A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced Cancer.
- Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase (PAP) in Patients with Castration-Resistant Prostate Cancer.
- Targeting androgen receptor and JunD interaction for prevention of prostate Cancer progression.
- A phase I study of vorinostat in combination with bortezomib in patients with advanced Malignancies.
- Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate Cancer (READY): a randomised, double-blind phase 3 trial.
- A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.
- Vorinostat in combination with bortezomib in patients with advanced Malignancies directly alters transcription of target genes.
- A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve...
- A Randomized Phase II Trial Evaluating Different Schedules of Zoledronic Acid on Bone Mineral Density in Patients With Prostate Cancer Beginning Androgen Deprivation T...
- A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung Cancer.
- A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate Cancer.
- Intermittent versus continuous androgen deprivation in prostate Cancer.
- Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1?-hydroxyvitamin D2 in patients with clinically localized prosta...
- Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate Cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
- Phase I study of continuous MKC-1 in patients with advanced or metastatic solid Malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) ...
Schools
University Of Massachusetts Medical School
Clinical Center At The Nih
University Ma Mem Hlthcare University Campus
Conditions Treated
- Anemia
- Colorectal Cancer
- Liver Cancer
- Melanoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Preferred Plus POS
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Cross Accord
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Medicare MCR
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
Education
-
National Institutes of Health Clinical Center -
University of Massachusetts -
University of Massachusetts Medical School
Hospital
-
University of Wisconsin Hospital and Clinics
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235190141 |
| Last Name Of The Provider | WILDING |
| First Name Of The Provider | GEORGE |
| View All |
Similar Doctors
|
|
Dr. Murtuza M. Rampurwala, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert B. Hegeman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joshua M. Lang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dustin A. Deming, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne M. Traynor, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Danielle B. Bol-De Greve, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adnan A. Zaidi, MD |